ABCB1 and breast carcinoma: Through down-regulating ABCB1, Apigenin (2, 8 μM) significantly enhances the efficacy of doxorubicin (Dox, an ABCB1 substrates) in its resistant MES-SA/Dx5 cells (85) and breast cancer cells (MCF7/ADR) (86).